Operator learning curve for transradial liver cancer embolization: implications for the initiation of a transradial access program.


Journal

Diagnostic and interventional radiology (Ankara, Turkey)
ISSN: 1305-3612
Titre abrégé: Diagn Interv Radiol
Pays: Turkey
ID NLM: 101241152

Informations de publication

Date de publication:
Sep 2019
Historique:
pubmed: 28 7 2019
medline: 19 2 2020
entrez: 27 7 2019
Statut: ppublish

Résumé

We aimed to analyze transradial access (TRA) learning curve on patients undergoing hepatic chemoembolization, investigating the relationship between procedural volumes and various benchmarks of procedural success. We enrolled 60 consecutive patients who received two unilobar hepatic chemoembolizations within a 4-week interval performed by a single interventional radiologist, highly-trained in conventional transfemoral access (TFA) procedures, but without any previous practical experience in TRA procedures and with a preliminary 2-day theoretical training only. Consecutive patients were prospectively enrolled and analyzed in 3 groups: A (cases 1 to 20), B (cases 21 to 40), and C (cases 41 to 60). All patients underwent one hepatic chemoembolization using TRA and the other one using TFA in random order. All TFA procedures performed by the same operator in the same series of patients were considered as the control group. Primary endpoint was to analyze the relationship between TRA procedure operator experience and benchmarks of procedural success, to define the optimal procedural learning curve. Technical success was obtained in all patients, with a crossover rate (radial to femoral access) of 0%. An association between incremental TRA operator experience (in terms of performed procedures) and decrease of preparation, puncture, fluoroscopy, and total examination times was observed. Similarly, inverse associations between incremental TRA operator experience and contrast medium (CM) volumes (P < 0.001) and radiation dose (RD) values (in terms of RAK - Reference Air Kerma) (P < 0.001) were also observed. Compared with TFA, CM volumes and RD values were significantly higher only in group A (cases 1-20). Procedure success remained high in all TRA groups and no significant association between TRA incremental experience and postprocedural outcomes was found. Higher postprocedural complaints at the access route and more limitations in performing basic activities were recorded after TFA vs. TRA (P < 0.001). TRA catheterizations can be safely performed in patients treated for liver cancer embolization after a relatively short training in controlled conditions and with a better performance in comparison with TFA. Operator proficiency improves with greater TRA experience, with a threshold needed to overcome the learning curve represented by about 20 procedures.

Identifiants

pubmed: 31348005
doi: 10.5152/dir.2019.18437
pmc: PMC6727820
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

368-374

Références

J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S293-5
pubmed: 14514836
J Clin Gastroenterol. 2003 Nov-Dec;37(5):412-7
pubmed: 14564191
Indian Heart J. 2008 Jan-Feb;60(1 Suppl A):A14-7
pubmed: 19359740
JACC Cardiovasc Interv. 2010 Apr;3(4):463; author reply 463-4
pubmed: 20398879
Lancet. 2011 Apr 23;377(9775):1409-20
pubmed: 21470671
Am J Cardiol. 2011 Jul 15;108(2):185-8
pubmed: 21530937
Am J Cardiol. 2011 Oct 15;108(8):1092-5
pubmed: 21798498
Circ Cardiovasc Interv. 2011 Aug;4(4):336-41
pubmed: 21813402
J Invasive Cardiol. 2012 Nov;24(11):599-604
pubmed: 23117316
Am Heart J. 2013 Mar;165(3):310-6
pubmed: 23453098
J Invasive Cardiol. 2014 Feb;26(2):80-6
pubmed: 24486667
J Vasc Interv Radiol. 2014 Mar;25(3):443-7
pubmed: 24581468
Cardiovasc Revasc Med. 2014 Jun;15(4):195-9
pubmed: 24746598
Circulation. 2014 Jun 3;129(22):2277-86
pubmed: 24756064
PLoS One. 2014 Nov 06;9(11):e111527
pubmed: 25375152
J Vasc Interv Radiol. 2016 Feb;27(2):159-66
pubmed: 26706186
Indian J Cancer. 2015 Dec;52 Suppl 2:e107-11
pubmed: 26728666
Diagn Interv Radiol. 2016 Sep-Oct;22(5):444-9
pubmed: 27353460
AJR Am J Roentgenol. 2016 Nov;207(5):1112-1121
pubmed: 27767350
J Vasc Interv Radiol. 2017 Jun;28(6):898-905
pubmed: 28396191
Interv Cardiol Clin. 2015 Apr;4(2):203-211
pubmed: 28582051
J Vasc Interv Radiol. 2017 Sep;28(9):1234-1239
pubmed: 28757286
J Vasc Interv Radiol. 2018 Jan;29(1):38-43
pubmed: 29150395
Cathet Cardiovasc Diagn. 1996 Dec;39(4):365-70
pubmed: 8958424

Auteurs

Roberto Iezzi (R)

Department of Bioimaging and Radiological Sciences, Candiolo Cancer Institute-IRCCS, Rome, Italy; Department of Radiological Sciences, Catholic University School of Medicine, Rome, Italy.

Alessandro Posa (A)

Department of Radiology, IRCCS Fatebenefratelli Hospital Foundation for Health Research and Education, Rome, Italy.

Biagio Merlino (B)

Department of Bioimaging and Radiological Sciences, Candiolo Cancer Institute-IRCCS, Rome, Italy; Department of Radiological Sciences, Catholic University School of Medicine, Rome, Italy.

Maurizio Pompili (M)

Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy.

Eleonora Annicchiarico (E)

Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy.

Elena Rodolfino (E)

Department of Bioimaging and Radiological Sciences, Candiolo Cancer Institute-IRCCS, Rome, Italy.

Michele Basso (M)

Department of Oncology, Catholic University School of Medicine, Rome, Italy.

Alessandra Cassano (A)

Department of Oncology, Catholic University School of Medicine, Rome, Italy.

Antonio Gasbarrini (A)

Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy.

Riccardo Manfredi (R)

Department of Bioimaging and Radiological Sciences, Candiolo Cancer Institute-IRCCS, Rome, Italy; Department of Radiological Sciences, Catholic University School of Medicine, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH